Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 11,586 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Opioid-use Disorder, Opioid Use, Opioid Abuse
Interventions: Choice Architecture Nudge, PMP Integration & Nudge; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Syncope
Interventions: Propranolol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Diseases
Interventions: smoking cessation; Behavioral
Lead sponsor: National Institutes of Health (NIH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Bosutinib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions: VCL-CB01, Phosphate-buffered Saline (PBS); Biological · Other
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bortezomib; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Rochester, Minnesota • Madison, Wisconsin

Conditions: Leukemia
Interventions: Nelarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis B
Interventions: Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Sacramento, California • San Jose, California • Colorado Springs, Colorado + 2 more

Conditions: Chronic Constipation
Interventions: TD-5108; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg); Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 9,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support; Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Gastonia, North Carolina • Charleston, South Carolina

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions: Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab; Drug · Other · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 291
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more

Conditions: Spinal Cord Injuries, Blood Pressure Disorders
Interventions: ARC-IM System Implantation, ARC-IM Therapy (Group 1), ARC-IM Therapy (Group 2); Procedure · Device
Lead sponsor: ONWARD Medical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Little Rock, Arkansas • Englewood, Colorado • Miami, Florida + 8 more

Conditions: Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions: Behavioral Counseling, bupropion-SR; Behavioral · Drug
Lead sponsor: Eva Szigethy; Other
Eligibility: 15 Years to 30 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 32
States / cities: Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in California, California + 29 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions: Ivacaftor 150 MG, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Brain Injuries, Brain Injuries, Traumatic, Injury, Brain, Traumatic, Traumatic Brain Injury, Brain Injury, Chronic
Interventions: CLSI, MI, CR, CLSI - Unknown; Behavioral
Lead sponsor: Center for Vision Development, New Market, Maryland; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Market, Maryland

Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, South Carolina

Conditions: Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions: ACZ885 150 mg (Canakinumab); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 20 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: Cerebral Palsy, Gait Disorders, Neurologic
Interventions: mPAD (or TPAD) Pelvic Assist Device, No Intervention; Device
Lead sponsor: Altec Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Natick, Massachusetts • New York, New York

Conditions: Breast Cancer
Interventions: Acupuncture, Questionnaires, Hand Function and Balance Tests; Procedure · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Use, Chronic Pain
Interventions: Yoga classes; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Leukemia, Myeloid, Chronic
Interventions: Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more

Search by objective public record fields.

PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Current Opioid-User Population

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance

Longitudinal Care: Smoking Reduction to Aid Cessation

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

PS-341 in Treating Patients With Advanced Cancer

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

How Well do Patients With Traumatic Brain Injury Learn New Material Using Learning Styles in Online Science Classrooms?

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

Precision Gait Retraining for Children With Cerebral Palsy

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase I

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™